OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10368	Companies
216052	Keywords
145770	Articles
114405	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 07/17/2025 at 09:00, 9 months 22 days ago

Oxurion sécurise le financement de l'acquisition d'Axiodis CRO et projette un closing de l'opération au 1eraoût 2025
Oxurion sécurise le financement et acquiert 72% d'Axiodis CRO, renforçant sa position dans la recherche clinique. Projet d'expansion en Europe. Informations sur www.oxurion.com

Acquisition Financement Europe Recherche Clinique Oxurion
BRIEF

published on 07/17/2025 at 08:35, 9 months 22 days ago

Oxurion Sécurise le Financement pour l'Acquisition d'Axiodis CRO

Acquisition Biopharmaceutique Données Cliniques Oxurion Axiodis CRO
BRIEF

published on 07/17/2025 at 08:35, 9 months 22 days ago

Oxurion Secures Financing for Major Acquisition

Acquisition Biopharmaceutical Clinical Data Oxurion Europe Hub
BRIEF

published on 07/17/2025 at 08:35, 9 months 22 days ago

Oxurion obtient un financement pour une acquisition majeure

Acquisition Biopharmaceutique Données Cliniques Oxurion Plateforme Européenne
PRESS RELEASE

published on 07/17/2025 at 08:30, 9 months 22 days ago

Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025
Oxurion NV secures financing for 72% stake in Axiodis CRO, enhancing its clinical data capabilities. Acquisition aligned with strategic roadmap for European hub. Closing set for August 1, 2025

Acquisition Clinical Data Oxurion NV Axiodis CRO European Hub
PRESS RELEASE

published on 07/17/2025 at 08:30, 9 months 22 days ago

Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een closing op 1 augustus 2025
Oxurion sichert Finanzierung für die Übernahme von Axiodis CRO ab und plant Abschluss der Transaktion am 1. August 2025

Übernahme Finanzierung Oxurion Klinische Daten Therapeutische Entwicklung
BRIEF

published on 07/15/2025 at 18:05, 9 months 23 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Shares Transparency Atlas Biopharmaceutical Oxurion
BRIEF

published on 07/15/2025 at 18:05, 9 months 23 days ago

Oxurion reçoit une notification de transparence d'Atlas Special Opportunities II LLC

Actions Atlas Transparence Biopharmaceutique Oxurion
PRESS RELEASE

published on 07/15/2025 at 18:00, 9 months 23 days ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian Transparency legislation

Transparency Notification Shareholding Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
PRESS RELEASE

published on 07/15/2025 at 18:00, 9 months 23 days ago

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV meldt ontvangst van transparantiekennisgeving en verlaagd aandelenposities onder wettelijke drempel. Biofarmaceutisch bedrijf in Leuven actief op gebied van therapeutische innovatie en klinisch onderzoek

Transparantiekennisgeving Euronext Brussel Oxurion NV Leuven Biofarmaceutisch

Accesswire

Published on 05/08/2026 at 10:30, 39 minutes ago

Previewing the Product Logic Behind Waton’s Next AI Trading Platform
Published on 05/08/2026 at 01:50, 9 hours 19 minutes ago

Apex Critical Metals Announces Grant of Stock Options and RSUs
Published on 05/08/2026 at 00:45, 10 hours 24 minutes ago

Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 11 hours 9 minutes ago

Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 11 hours 39 minutes ago

Faraday Copper Reports First Quarter 2026 Financial Results

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 10:48, 21 minutes ago

Notice to holders of the MTU Aero Engines AG (the “Issuer”) €600 million 0.000% Convertible Bonds Due 2033 (the “Bonds”)
Published on 05/08/2026 at 10:25, 44 minutes ago

Original-Research: Mister Spex SE (von Quirin Privatbank Kapitalmarktgeschäft): Hold
Published on 05/08/2026 at 10:08, 1 hour 1 minute ago

Previewing the Product Logic Behind Waton’s Next AI Trading Platform
Published on 05/08/2026 at 10:00, 1 hour 8 minutes ago

Original-Research: Finexity AG (von GBC AG): Buy
Published on 05/08/2026 at 10:00, 1 hour 9 minutes ago

Sto SE & Co. KGaA: Unfavourable weather conditions and construction downturn at the start of the year impact business development in the first quarter of 2026

Les Echos

Published on 05/07/2026 at 19:15, 15 hours 54 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 15 hours 54 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 16 hours 3 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 16 hours 3 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 16 hours 9 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE